MARLBOROUGH, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (“ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, and its collaborators reported today that it has discovered a new method to generate a potent and replenishable population of mesenchymal stem cells (MSCs) from pluripotent stem cells. The research appears online ahead of print in Stem Cell and Development, one of the top stem cells journals, published by Mary Ann Liebert, Inc. This new and proprietary population of pluripotent stem cell-derived MSCs displays potent immunomodulatory and therapeutic properties and has a greater than 30,000 fold proliferative capacity, relative to ordinary bone marrow-derived MSCs, the most commonly used source for MSCs in clinical trials. The paper is available free online at http://online.liebertpub.com/doi/abs/10.1089/scd.2013.0554.
Help employers find you! Check out all the jobs and post your resume.
